Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Bladder Cancer

  Free Subscription


1 Anal Chem
1 Ann Diagn Pathol
1 Ann Vasc Surg
1 Asian Pac J Cancer Prev
1 Bioengineered
1 Biosensors (Basel)
2 BMC Cancer
1 BMC Urol
1 Braz J Med Biol Res
1 Cancer Biother Radiopharm
1 Cancer Immunol Immunother
1 Cancer Manag Res
5 Curr Opin Urol
1 Eur J Nutr
1 Eur J Surg Oncol
1 Eur Urol Open Sci
1 Front Genet
1 Front Immunol
1 Front Med (Lausanne)
2 Hinyokika Kiyo
1 Immunology
1 Immunotherapy
1 Int J Urol
1 Int Urol Nephrol
1 J Cancer Res Clin Oncol
1 J Clin Oncol
1 Oncology
2 Pediatr Blood Cancer
1 Radiol Med
1 Radiology
1 Sci Rep
1 Sci Total Environ
1 Urol Oncol
1 Urology
1 Wiad Lek
5 World J Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Anal Chem

  1. LI Y, Jiang L, Wang Z, Wang Y, et al
    Profiling of Urine Carbonyl Metabolic Fingerprints in Bladder Cancer Based on Ambient Ionization Mass Spectrometry.
    Anal Chem. 2022 Jun 28. doi: 10.1021/acs.analchem.2c01890.
    PubMed         Abstract available

    Ann Diagn Pathol

  2. PUZYRENKO A, Nomani L, Iczkowski K, Giorgadze T, et al
    Small cell carcinoma of the urinary bladder: Distinctive cytological characteristics and Cyto-histologic correlation.
    Ann Diagn Pathol. 2022;59:151947.
    PubMed         Abstract available

    Ann Vasc Surg

  3. HO KKF, Lal V, Hagley D, Bingley J, et al
    Systematic Review of Case Reports of Bacillus Calmette-Guerin Vascular Infections.
    Ann Vasc Surg. 2022;83:369-377.
    PubMed         Abstract available

    Asian Pac J Cancer Prev

  4. KHALIL H, Hammam OA, Kamel A
    Detection of Epithelial-Mesenchymal Transition Markers in High Grade Bladder Cancer and Special Variants of Urothelial Carcinoma.
    Asian Pac J Cancer Prev. 2022;23:2079-2087.
    PubMed         Abstract available


  5. SUN X, Xin S, Jin L, Zhang Y, et al
    Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer.
    Bioengineered. 2022;13:13986-13999.
    PubMed         Abstract available

    Biosensors (Basel)

  6. KIM Y, Choi WJ, Oh J, Kim JK, et al
    Compact Smartphone-Based Laser Speckle Contrast Imaging Endoscope Device for Point-of-Care Blood Flow Monitoring.
    Biosensors (Basel). 2022;12.
    PubMed         Abstract available

    BMC Cancer

  7. LI JD, Farah AA, Huang ZG, Zhai GQ, et al
    Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
    BMC Cancer. 2022;22:713.
    PubMed         Abstract available

  8. HOU J, Lu Z, Cheng X, Dong R, et al
    Ferroptosis-related long non-coding RNA signature predicts the prognosis of bladder cancer.
    BMC Cancer. 2022;22:719.
    PubMed         Abstract available

    BMC Urol

  9. MAHMOUD AM, Frank I, Orme JJ, Lavoie RR, et al
    Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer.
    BMC Urol. 2022;22:90.
    PubMed         Abstract available

    Braz J Med Biol Res

  10. Erratum notice for: "Suppressive effect of platycodin D on bladder cancer through microRNA-129-5p-mediated PABPC1/PI3K/AKT axis inactivation" [Braz J Med Biol Res 2021;54(3):e10222].
    Braz J Med Biol Res. 2022;55:e10222erratum.
    PubMed         Abstract available

    Cancer Biother Radiopharm

  11. XIAO Y, He L, Dong Y, Huang Y, et al
    Highly Expressed LINC00958 Modulates the Growth and Epithelial-Mesenchymal Transition of Bladder Cancer Cells Through SAPK/JNK Signaling Pathway.
    Cancer Biother Radiopharm. 2022 Jun 29. doi: 10.1089/cbr.2022.0005.
    PubMed         Abstract available

    Cancer Immunol Immunother

  12. VAN WILPE S, Sultan S, Gorris MAJ, Somford DM, et al
    Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome.
    Cancer Immunol Immunother. 2022 Jun 30. pii: 10.1007/s00262-022-03234.
    PubMed         Abstract available

    Cancer Manag Res

  13. Novel lncRNA LINC01614 Facilitates Bladder Cancer Proliferation, Migration and Invasion Through the miR-217/RUNX2/Wnt/beta-Catenin Axis [Retraction].
    Cancer Manag Res. 2022;14:2105-2106.
    PubMed         Abstract available

    Curr Opin Urol

    Editorial: Medical, technical and functional aspect of various types of urinary diversion.
    Curr Opin Urol. 2021;31:542-543.

  15. GRAUER R, Wiklund NP
    Update on robotic cystectomy.
    Curr Opin Urol. 2021;31:537-541.
    PubMed         Abstract available

  16. LIEDBERG F, Bobjer J
    Urinary diversions for benign and oncologic indications: what did we learn about short term complications in the last 24 months?
    Curr Opin Urol. 2021;31:556-561.
    PubMed         Abstract available

  17. NUIJENS ST, Cobussen-Boekhorst H, Heesakkers JPFA, Witjes JA, et al
    Patient-reported outcomes and health-related quality of life after urinary diversions.
    Curr Opin Urol. 2021;31:574-579.
    PubMed         Abstract available

  18. VAN 'T HOF MEM, Bruins HM, van Roermund JGH
    Management of upper urinary tract problems after radical cystectomy for urothelial carcinoma: tips and tricks.
    Curr Opin Urol. 2021;31:570-573.
    PubMed         Abstract available

    Eur J Nutr

  19. LEEMING RC, Koutros S, Karagas MR, Baris D, et al
    Diet quality, common genetic polymorphisms, and bladder cancer risk in a New England population-based study.
    Eur J Nutr. 2022 Jun 27. pii: 10.1007/s00394-022-02932.
    PubMed         Abstract available

    Eur J Surg Oncol

  20. LIN L, Guo X, Ma Y, Zhu J, et al
    Does repeat transurethral resection of bladder tumor influence the diagnosis and prognosis of T1 bladder cancer? A systematic review and meta-analysis.
    Eur J Surg Oncol. 2022 Jun 13. pii: S0748-7983(22)00489.
    PubMed         Abstract available

    Eur Urol Open Sci

  21. DE NUNZIO C, Lombardo R, Cicione A
    Early or Delayed Radical Cystectomy for High-risk Non-muscle-invasive Bladder Cancer: A Hard Dilemma to Solve.
    Eur Urol Open Sci. 2022;42:17-18.

    Front Genet

  22. YAO J, Liu Y, Yang J, Li M, et al
    Single-Cell Sequencing Reveals that DBI is the Key Gene and Potential Therapeutic Target in Quiescent Bladder Cancer Stem Cells.
    Front Genet. 2022;13:904536.
    PubMed         Abstract available

    Front Immunol

  23. YE F, Liang Y, Cheng Z, Liu Y, et al
    Immunological Characteristics of Alternative Splicing Profiles Related to Prognosis in Bladder Cancer.
    Front Immunol. 2022;13:911902.
    PubMed         Abstract available

    Front Med (Lausanne)

  24. BAI Y, Wang H, Wu X, Weng M, et al
    Study on Molecular Information Intelligent Diagnosis and Treatment of Bladder Cancer on Pathological Tissue Image.
    Front Med (Lausanne). 2022;9:838182.
    PubMed         Abstract available

    Hinyokika Kiyo

  25. TAKAHASHI R, Kinase S, Yanagihashi R, Ishitsuka R, et al
    [A Case of Reactive Arthritis after BCG Intravesical Infusion Therapy Successfully Treated with Salazosulfapyridine].
    Hinyokika Kiyo. 2022;68:145-148.
    PubMed         Abstract available

  26. YAMAGUCHI R, Shimizu Y, Nakayasu R, Utsunomiya N, et al
    [A Case of Bladder Plasmacytoma Diagnosed during Treatment of Multiple Myeloma].
    Hinyokika Kiyo. 2022;68:149-153.
    PubMed         Abstract available


  27. WU X, Wei Y, Lin R, Chen P, et al
    Multi-responsive mesoporous polydopamine composite nanorods cooperate with nano-enzyme and photosensitizer for intensive immunotherapy of bladder cancer.
    Immunology. 2022 Jun 25. doi: 10.1111/imm.13534.
    PubMed         Abstract available


  28. BARBUR E, Doganca T, Obek C
    Safe use of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer during breastfeeding: a case report.
    Immunotherapy. 2022 Jun 27. doi: 10.2217/imt-2021-0203.
    PubMed         Abstract available

    Int J Urol

  29. TANAKA T, Shindo T, Hashimoto K, Kobayashi K, et al
    Management of hydronephrosis after radical cystectomy and urinary diversion for bladder cancer: A single tertiary center experience.
    Int J Urol. 2022 Jun 30. doi: 10.1111/iju.14970.
    PubMed         Abstract available

    Int Urol Nephrol

  30. JAFFER A, Lee M, Khalil O, Raslan M, et al
    The natural history of low-risk non-muscle-invasive bladder cancer: a collaborative multi-centre study.
    Int Urol Nephrol. 2022 Jun 27. pii: 10.1007/s11255-022-03264.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  31. SAEEDIAN A, Safaei AM, Azimi A, Kolahdouzan K, et al
    Implications for pelvic lymph node irradiation in definitive chemoradiotherapy of node negative muscle invasive bladder cancer based on predictive factors of clinicopathologic discrepancy.
    J Cancer Res Clin Oncol. 2022 Jun 28. pii: 10.1007/s00432-022-04153.
    PubMed         Abstract available

    J Clin Oncol

  32. GRIMM MO, Schmitz-Drager BJ, Zimmermann U, Grun CB, et al
    Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
    J Clin Oncol. 2022;40:2128-2137.
    PubMed         Abstract available


  33. NODA Y, Naiki T, Sugiyama Y, Nagai T, et al
    Survival outcome after reduced-port laparoscopic radical cystectomy for bladder cancer: long-term follow-up analysis.
    Oncology. 2022 Jun 27. pii: 000525554. doi: 10.1159/000525554.
    PubMed         Abstract available

    Pediatr Blood Cancer

  34. AKKARY R, Guerin F, Chargari C, Jochault L, et al
    Long-term urological complications after conservative local treatment (surgery and brachytherapy) in children with bladder-prostate rhabdomyosarcoma: A single-team experience.
    Pediatr Blood Cancer. 2022;69:e29532.
    PubMed         Abstract available

  35. LOBO S, Gaze MN, Slater O, Hoskin P, et al
    Bladder function after conservative surgery and high-dose rate brachytherapy for bladder-prostate rhabdomyosarcoma.
    Pediatr Blood Cancer. 2022;69:e29574.
    PubMed         Abstract available

    Radiol Med

  36. BICCHETTI M, Simone G, Giannarini G, Girometti R, et al
    A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study.
    Radiol Med. 2022 Jun 28. pii: 10.1007/s11547-022-01513.
    PubMed         Abstract available


  37. WANG HJ, Cai Q, Huang YP, Li MQ, et al
    Amide Proton Transfer-weighted MRI in Predicting Histologic Grade of Bladder Cancer.
    Radiology. 2022 Jun 28:211804. doi: 10.1148/radiol.211804.
    PubMed         Abstract available

    Sci Rep

  38. KIJIMA T, Kubo T, Nishihara D, Nukui A, et al
    Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients.
    Sci Rep. 2022;12:10617.
    PubMed         Abstract available

    Sci Total Environ

  39. MARTIN-WAY D, Puche-Sanz I, Cozar JM, Zafra-Gomez A, et al
    Genetic variants of antioxidant enzymes and environmental exposures as molecular biomarkers associated with the risk and aggressiveness of bladder cancer.
    Sci Total Environ. 2022 Jun 25:156965. doi: 10.1016/j.scitotenv.2022.156965.
    PubMed         Abstract available

    Urol Oncol

  40. POHAR KS, Patel S, Lotan Y, Trabulsi E, et al
    Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study.
    Urol Oncol. 2022 Jun 21. pii: S1078-1439(22)00144.
    PubMed         Abstract available


  41. BENIDIR T, Lone Z, Zhang A, Nowacki AS, et al
    Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer when treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy.
    Urology. 2022 Jun 27. pii: S0090-4295(22)00514.
    PubMed         Abstract available

    Wiad Lek

  42. JAKIMOW K, Sznajder K
    Wiad Lek. 2022;75.
    PubMed         Abstract available

    World J Urol

  43. DEL GIUDICE F, Flammia RS, Pecoraro M, Moschini M, et al
    The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations.
    World J Urol. 2022;40:1617-1628.
    PubMed         Abstract available

  44. ARORA A, Zugail AS, Pugliesi F, Cathelineau X, et al
    Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy.
    World J Urol. 2022;40:1697-1705.
    PubMed         Abstract available

  45. VEJLGAARD M, Maibom SL, Joensen UN, Thind PO, et al
    Quality of life and secondary outcomes for open versus robot-assisted radical cystectomy: a double-blinded, randomised feasibility trial.
    World J Urol. 2022;40:1669-1677.
    PubMed         Abstract available

  46. LAUKHTINA E, Boehm A, Peyronnet B, Bravi CA, et al
    Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study.
    World J Urol. 2022;40:1689-1696.
    PubMed         Abstract available

  47. MENDREK M, Witt JH, Sarychev S, Liakos N, et al
    Reporting and grading of complications for intracorporeal robot-assisted radical cystectomy: an in-depth short-term morbidity assessment using the novel Comprehensive Complication Index((R)).
    World J Urol. 2022;40:1679-1688.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.